Drug profile · INN
autologous glioma tumor cell lysates (inactivated)
SITOIGANAP
autologous glioma tumor cell lysates (inactivated) (SITOIGANAP) is an FDA-listed pharmaceutical active ingredient.
EMA: application withdrawn Antineoplastic and immunomodulating agents (L01) L01XX
Patents linked 0
Pipeline programs 19
News articles 0
Drug details — autologous glioma tumor cell lysates (inactivated)
- Class
- Antineoplastic and immunomodulating agents (L01)
- Route
- —
- Patents
- 0
- Programs
- 19
- Data quality
- 0.83
Quick answer
autologous glioma tumor cell lysates (inactivated) (SITOIGANAP) is an FDA-listed pharmaceutical active ingredient.
Key facts
INN autologous glioma tumor cell lysates (inactivated)
Brand SITOIGANAP
Therapeutic class Antineoplastic and immunomodulating agents (L01)
ATC code L01XX
Approval history
| Authority | Status | Date |
|---|---|---|
| EMA | application withdrawn | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is autologous glioma tumor cell lysates (inactivated)?
autologous glioma tumor cell lysates (inactivated) (SITOIGANAP) is an FDA-listed pharmaceutical active ingredient.
What is the brand name for autologous glioma tumor cell lysates (inactivated)?
SITOIGANAP is a marketed brand name for autologous glioma tumor cell lysates (inactivated). Check FDA Drugs@FDA for the current US label holder and prescribing information.